ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) (“ImmunoCellular” or the “Company”), today announced second quarter results for the period ended June 30, 2012.
Highlights of the second quarter and recent weeks include:
- Ended second quarter with $11.3 million cash, sufficient to fund next 12 months of operations
- Qualified and listed on the NYSE MKT
- Added to the Russell 3000®, Global and Microcap Indexes
Clinical and Business Highlights:
- ICT-107 Phase I clinical data was accepted for publication in prestigious peer-reviewed medical journal: Cancer Immunology, Immunotherapy
- Expanded enrollment of Phase II clinical trial of ICT-107
- Presented long-term survival data from Phase I study of ICT-107 at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
- Brought online second manufacturing site for ICT-107 at a facility run by Progenitor Cell Therapy (PCT)
- FDA clearance of new IND application for Phase I trial of ICT-121
- Received important Japanese patent relating to technology for the treatment of brain cancer
|Condensed Balance Sheets|
|Other current assets||618,086||91,286|
|Non current assets||106,484||406,303|
|Condensed Statement of Operations (Unaudited)|
|3 monthsended6/30/2012||3 monthsended6/30/2011||6 monthsended6/30/2012||6 monthsended6/30/2011|
|Research and development||2,189,633||858,183||4,188,169||1,775,397|
|Stock based compensation||103,617||391,858||348,724||633,839|
|General and administrative||837,322||579,889||1,643,120||1,133,610|
|Loss before other expenses||(3,130,572||)||(1,829,930||)||(6,180,013||)||(3,542,846||)|
|Change in fair value of warrant liability||(3,323,220||)||278,096||(7,795,724||)||(768,895||)|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV